CRISPR Therapeutics AG — Director's Dealing 2016

Oct 18, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: Subramanian Kala (See Remarks)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$12.57	2026-07-01	Common Shares (133333)		Direct
Stock Option (Right to Buy)	$12.57	2026-07-01	Common Shares (33333)		Direct

Footnotes

F1: This option was granted on July 1, 2016 with respect to 133,333 Common Shares with 25% of the shares vesting on June 27, 2016, the first anniversary of employment commencement, and the remaining 75% vest in 36 equal monthly installments thereafter.

F2: This performance-based option was granted on July 1, 2016 with respect to 33,333 Common Shares with 100% of the shares vesting within 12 months of the commencement of Ms. Subaramian's employment, subject to the satisfaction of mutually agreed upon performance metrics.